Differential effects of heat shock protein 90 and serine 1179 phosphorylation on endothelial nitric oxide synthase activity and on its cofactors
Open Access
- 27 June 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6), e0179978
- https://doi.org/10.1371/journal.pone.0179978
Abstract
Endothelial nitric oxide synthase (eNOS) is responsible for maintaining systemic blood pressure, vascular remodeling and angiogenesis. Previous studies showed that bovine eNOS serine 1179 (Serine 1177 for human eNOS) phosphorylation enhanced NO synthesis. Meanwhile, heat shock protein 90 (Hsp90) plays a critical role in maintenance of eNOS structure and function. However, the regulatory difference and importance between Serine 1179 phosphorylation and Hsp90 on eNOS activity have not been evaluated. In current studies, S1179D eNOS was employed to mimic phospho-eNOS and exhibited markedly increased enzyme activity than wild type eNOS (WT eNOS). Hsp90 showed a dose-dependent increase for both WT eNOS and S1179D eNOS activity at the presence of all eNOS cofactors, such as Calcium/Calmodulin (Ca2+ /CaM), BH4, and NADPH etc. The enhancement effects were abolished by dominant-negative mutant Hsp 90 protein. ENOS-cofactors dynamic assay showed that Hsp90 enhanced WT eNOS affinity to NADPH, L-arginine, and CaM but not to Ca2+ and BH4. The impact of eNOS Serine 1179 phosphorylation and Hsp90 on eNOS affinity to cofactors has also been compared. Different from the effect of Hsp90 on eNOS affinity to specific cofactors, Serine 1179 phosphorylation significantly increased eNOS affinity to all cofactors. Moreover, VEGF-induced eNOS phosphorylation in bovine aortic endothelial cells (BAECs) and more NO generation from eNOS compared to control. Inhibition of Hsp90 by geldanamycin decreased eNOS activity and decreased endothelial viability. In conclusion, by changing eNOS structure, Hsp90 profoundly affected eNOS functions, including change of affinity of eNOS to cofactors like Ca2+, L-arginine, BH4 and further affecting NO generation capability. These specific cofactors regulated by Hsp 90 could become potential therapeutic targets of the eNOS-related diseases in future.Keywords
Funding Information
- National Scientific Foundation of China (81671938)
- National Scientific Foundation of China (81501696)
This publication has 27 references indexed in Scilit:
- Vascular effects of linagliptin in non‐obese diabetic mice are glucose‐independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin‐1 (CAV‐1) pathwayDiabetes, Obesity and Metabolism, 2016
- Inhibitor-κB kinase attenuates Hsp90-dependent endothelial nitric oxide synthase function in vascular endothelial cellsAmerican Journal of Physiology-Cell Physiology, 2015
- Regulation of eNOS Enzyme Activity by Posttranslational ModificationCurrent Pharmaceutical Design, 2014
- AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr495 and Ser1177Biochemical and Biophysical Research Communications, 2013
- Structure, Function and Regulation of the Hsp90 MachineryBiomedical Journal, 2013
- Nitric oxide synthases: regulation and functionEuropean Heart Journal, 2011
- Functional Reconstitution of Endothelial Nitric Oxide Synthase Reveals the Importance of Serine 1179 in Endothelium-Dependent VasomotionCirculation Research, 2002
- Enhanced Electron Flux and Reduced Calmodulin Dissociation May Explain “Calcium-independent” eNOS Activation by PhosphorylationPublished by Elsevier BV ,2000
- Regulation of endothelium-derived nitric oxide production by the protein kinase AktNature, 1999
- The L-Arginine-Nitric Oxide PathwayThe New England Journal of Medicine, 1993